The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis

Current Medical Research and Opinion, Supplement

Volumn 23, Issue 1, 2007, Pages

  Currie, Craig J ^a,d   Poole, Chris D ^b   Tetlow, Tony ^b   Holmes, Paul ^c   McEwan, Phil ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Cardiff Research Consortium   (United Kingdom)

^c Sanofi Aventis UK   (United Kingdom)

^d Pharma Research Centre   (United Kingdom)

Author keywords

Diabetes; Effectiveness; Glycaemia; HbA1c; Hypoglycaemia; Outcome; Short acting insulin; Weight

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CODING; RETROSPECTIVE STUDY; SIDE EFFECT; UNITED KINGDOM; WEIGHT CHANGE; WEIGHT GAIN;

EID: 33947392874     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X167534     Document Type: Article

References (18)

1. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Science 2002;102:679-9
2. Bagust A, Evans M, Beale S, et al. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies Pharmacoeconomics 2006;24(Suppl 1):5-19
3. Conlon JM. Evolution of the insulin molecule: insights into structure-activity and phylogenetic relationships. Peptides 2001;22:1183-93
4. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006;66:31-49
5. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Int Med 2005;165:1337-44
6. Barton S. Which clinical studies provide the best evidence? BMJ 2000;321:255-6
7. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003;25:1541-77
8. Soran H, Younis N. Insulin detemir: a new basal insulin analogue. Diabetes Obes Metab 2006;8:26-30
9. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE901 versus NPH insulin patients with type 1 diabetes. Diabetes Care 2000;23:157-62
10. THIN [http://www.epic-uk.org/thin.htm] (accessed 21st April 2006]
11. GRRD [http://www.gprd.com/home/] (accessed 21st April 2006)
12. Brown PJB, Warmington V, Laurence M, et al. Randomised crossover trial comparing the performance of Clinical Terms Version 3 and Read Codes 5 byte set coding schemes in general practice. BMJ 2003;326:1127-30
13. Gallen I, Carter C. Prospective audit of the introduction of insulin glargine (Lantus) into clinical practice in type 1 diabetes. Practical Diabetes Int 2004;21:110-14
14. Fischer JS, McLaughlin T, Loza L, et al. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin 2004;20:1703-10
15. Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-8
16. Ruhnau KJ, Schneider K, Schweitzer MA. Introduction of insulin glargine to basal-bolus therapy improves metabolic control in patients with type 2 diabetes in everyday clinical practice. Diabetologia 2005;48(Suppl 1):A303
17. Diabetes (types 1 and 2) - long acting insulin analogues (No. 53). London, National Institute for Health and Clinical Excellence [http://www.nice.org.uk/page.aspx?o=TA053] (accessed 21st April 2006)
18. Poole CD, Tetlow T, McEwan P, et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S41-48